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An Animal Model of Bullous Pemphigoid 
Although bullous pemphigoid (BP) is characterized in part by the 
presence of IgG antibodies that bind at the basement membrane 
zone (BMZ) of stratified squamous epithelium, the exact role of the 
IgG in the pathogenesis ofBP is not known. One problem in under-
standing the role of the anti-BMZ autoantibodies has been that 
passive transfer experiments of human IgG to animal models have 
not in general been successful in eliciting inflammatory reactions. In 
addition, the recent determination that a major BP antigen, the 
230-kD BPAG 1, is an entirely intracellular antigen has added an-
other confounding factor to the pathogenic role of IgG autoanti-
bodies against BPAG1. In this issue of the Journal, Hall and 
co-workers (p. 9) have attempted to address this issue. They hy-
pothesized that because patients have been reported to both develop 
and exacerbate BP on exposure to ultraviolet (UV) light, animals 
that have a high-titer anti-BMZ antibody circulating might develop 
inflammatory disease similar to that seen in BP after UV exposure. 
They immunized rabbits with a 19 amino acid peptide encoded for 
by the BPAG1 eDNA, which in previous studies they had demon-
strated reacted with sera from 37% of patients with BP. The animals 
immunized with the BP AG 1 peptide developed rabbit IgG antibod-
ies that bound to normal human skin and rabbit skin in a manner 
similar to that that occurred in patients with BP. The animals, 
however, did not develop any clinical skin changes, nor did they 
have detectable immunoreactants at the BMZ on direct immuno-
fluorescence after the immunizations alone. When the immune 
animals were treated with UVB light, however, an enhanced in-
flammatory response with delayed wound healing was noted with 
polymorphonuclear leukocyte infiltrates present on histologic ex-
amination. After healing, linear deposits of rabbit IgG and C3 at the 
BMZ in a pattern identical to that found in patients with BP were 
present in the rabbits immunized with the BP peptide but not in 
control rabbits. Control rabbits developed only a short-lived ery-
thema. These observations suggest that one potential mechanism 
for the development of inflammatory disease in patients with anti-
bodies against BPAG 1 and other intracellular antigens may be that 
minor trauma, either by UV light or other mechanisms, exposes the 
target antigen(s) to circulating antibody and leads to the develop-
ment of clinical signs of inflammation. This model may prove use-
ful for examining the role of other regions of the BP AG 1 in induc-
ing inflammatory disease as well as for investigating the interactions 
between different antigens important in inducing the clinical mani-
festations of BP. 
Cloned Human TILs and Autologous Tumor Cells: Where's the Interaction? 
How do tumor-infiltrating lymphocytes (TILs) exert their anti-tu-
mor effects? Do they act by direct contact and lysis of tumor cells or 
do they release pro-inflammatory cytokines such as interferon and 
tumor necrosis factor that are tumorocidal? Recognition and rejec-
tion of tumor cells is mediated in part by tumor-specific antigens. 
However, there is a high degree of surface antigen heterogeneity 
between melanomas from different individuals and among primary 
and metastatic lesions in a single patient. T lymphocytes playa role 
in host recognition of tumor antigens. They also produce cytokines 
after activation by interleukin-2 (IL-2). In a study designed to ex-
plore the importance of these interactions, Becker and his co-
workers (p. 15) developed cell lines from primary and secondary 
melanomas. In addition, autologous tumor-specific T cells were 
isolated and cloned by limiting dilution after expansion of the cul-
tures; low levels of IL-2 added to the culture medium increased 
c1onin~. e~ciency;, Th~ :esultant T-cell clones did not express in-
herent killer cell aCtiVity and there was no correlation of CD4 or 
CD8 expression with the tumor site of origin. 
These investigators measured growth stimulation and cytokine 
production ofTILs in response to the primary and secondary tumor 
populations. They also assayed direct lysis of tumor cells by the 
various TIL clones. Their results show that primary melanomas 
could stimulate proliferation and cytokine production by secondary 
TIL clones, but secondary melanomas could not stimulate either 
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function in TILs isolated from primary tumors. On the other hand, 
TILs from secondary tumors could promote lysis of primary or 
secondary autologous melanomas, but primary site-derived TILs 
had no cytolytic activity. This indicates that the interaction is le-
sion-specific and implies that there is a loss of tumor antigen expres-
sion with progression of the tumor. These data expand earlier work 
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
by using clonal populations of cel ls and provide a defined system for 
the analysis host anti-tumor immunoresponse as well as tumor· 
escape mechanisms. The work may facilitate anti-tumor immuno· 
therapy by establishing a more efficient means of producing cyto· 
toxic lymp hocytes. 
Mutants and Missing Melanocytes 
Piebaldism is a rare genetic disorder with a long and visible history. 
Families have been chronicled since ancient times in which affected 
individuals display congenital white patches of skin and hair. Sev-
eral recent pedigrees exhibiting dominant autosomal inheritance 
can be traced back over hundreds of years. Disruption of prolifera-
tion or the pattern of neural crest outgrowth during development is 
thought to be responsible for the absence of melanocytes and the 
non-progressive nature of the patches. "Dominant white spotting" 
(W) is a similar disorder in mice. In addition to the non-pigmented 
spots, affected animals have defects in hematopoiesis and germ-cell 
development. Characterization of the genetic abnormality in mice 
showed a correlation with mutation or deletion of the KIT proto-
oncogene. Further studies of human subjects show a close parallel 
of piebaldism with the alterations found in "white spotting." The 
KIT proto-oncogene encodes a cell surface receptor for mast/stem 
cell growth-factor receptor. The receptor protein is made up of an 
extracellular region that binds the growth factor, a short trans-
membrane segment, and an intracellular domain with tyrosine ki-
nase activity. Mast/stem cell growth-factor binding causes two 
molecules of receptor protein to associate as a dimer. This initiates 
signal transduction by activating the kinase function of the com' 
plex. 
In this issue Spritz et al (p. 22) discuss two new mutations asso· 
ciated with piebaldism. Coding and flanking regions within the 
KIT gene of affected individuals from two different kind reds were 
amplified and checked for single-strand conformation polymor· 
ph isms (SSCP) and heteroduplex (HDX) alterations. Direct se· 
quence analysis of the products showed the presence of mutations in 
two of the most highly conserved portions of the tyrosine kinase 
domain. Both mutations are likely to have a dominant-negative 
effect on kinase activity, such that receptor dimers containing even 
one mutant peptide will have impaited function. This predicts that a 
heterozygous individual will have a 75% decrease in the ability of 
mast/stem cell growth factor to elicit a respollse through its recep' 
tor. Analysis of these mutations in mouse and man help to microdis· 
sect the critical elements in the function of the KIT proto-oncogene 
product. As the menu of permissible mutants is enlarged we will 
gain a better understanding of the role for this receptor in the nor-
mal developmental program of melanocytes and hematopoietic 
stem cel1s. 
Induced Tolerance to Heavy Metal 
Many people find heavy metal irritating in more than rock and roll. 
Nickel and chromium can and do cause contact sensitization, which 
can lead to serious metal dermatitis. Whereas antigens introduced 
through the skin generally cause sensitization, oral administration 
can lead to systemic immune tolerance. A retrospective study of 
nickel sensitivity ill humans has recently indicated that a previous 
oral contact with nickel may decrease the development of nickel 
sensitivity. Ingrid Van Hoogstraten and her colleagues describe in 
this issue (p. 26) a mouse model that offers an explanation for earlier 
problems of fai lure to sensitize mice epicutaneously with nickel. By 
maintaining the animals in a nickel-free environment for at least 
two generations the authors achieved a highly reproducible sensiti-
zation to nickel, whereas animals raised in cages with nickel-releas-
ing covers developed only minimal hypersensitivity. Confirmation 
of the role of oral tolerance in this model was achieved by the oral 
administration of nickel prior to sensitization, which produced an 
antigen specific, dose-dependent suppression of delayed hypersensi-
tivity to nickel. The cellular nature of this hypo responsiveness 
could be shown by CD8+ cell transfer and the persistence of the 
tolerance. This model system permits the exploitation of exten-
sively characterized mouse genetics and immunology for insights 
into the molecular basis of oral tolerance to the clinically relevant 
metal allergens. 
Secretion of a Neurotransmitter by Keratinocytes 
It has been fo und previously that nerve growth factor is among the 
increasing number of biologically active compounds secreted by 
epidermal keratinocytes. This suggests that keratinocytes may in-
fluence neural growth and function. In this issue Grando et af (p. 32) 
present evidence that kera.tinocytes produce another compou.nd tar-
geting nerves, acetylcho l111~. ~urthermore, bec~use the actIOns of 
acetylcholine may not be limited to the tradmonally recogl1lzed 
action as a neurotransmitter for parasympathetic nerves but also may 
affect some target tissues directly through non-synaptic receptors 
(summarized by Grando et aD, there may be a role for keratinocytes 
in influencing vicinal cells and structures by their secretion of ace-
tylcholine. These authors show by immunohistochemistry and by 
enzyme assay that human keratinocytes contain an enzyme in the 
acetylcholine biosynthetic pathway, choline acetyltransferase, that 
they synthesize acetylcholine, and that they can metabolize the 
compound. In other studies Grando et af propose that acetylcholine 
may also directly influence keratinocytes, raising the possibility that 
it acts in an autocrine fashion. These findings raise the prospect of 
yet another "cytokine" produced by keratinocytes and yet another 
mechanism by which keratinocytes may have an influence locally, 
on nearby cells, and may also themselves be influenced by both local 
and systemic events. A great deal of work will be required to exam-
ine the potential importance of acetylcholine in the skin. 
